Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma

Shunli Peng, Rong Wang, Yuling Zhou, Wei Wei, Guihua Zhong, Xiaotao Huang, Shuai Yang, Qiaodan Liu, Zhigang LiuFrontiers in Immunology 2022 · DOI

TL;DR

This study introduces a novel "Metabolism Score" derived from 14 key metabolic genes to predict patient outcomes in lung adenocarcinoma (LUAD), particularly for those treated with radiation therapy. This score not only correlates with survival and response to immunotherapy but also sheds light on the complex interplay between tumor metabolism, the immune microenvironment, and drug sensitivity, offering new avenues for personalized cancer treatment.

What Problem Does This Paper Address?

Lung adenocarcinoma (LUAD) is a major cause of cancer-related deaths, and while radiation therapy (RT) is a standard treatment, many patients develop resistance, leading to poor outcomes. Understanding the metabolic differences between radiosensitive and radioresistant tumors is crucial for developing better therapeutic strategies. Current research has explored metabolic reprogramming in cancer, but a comprehensive model that links these metabolic changes to radiosensitivity, immune response, and drug vulnerability in LUAD, especially post-RT, has been lacking. This paper aims to bridge this gap by developing a prognostic model based on metabolic signatures.

Methods

The researchers began by establishing a radioresistant LUAD cell line (A549RR) from its parent cell line (A549) through intermittent radiation exposure. They then performed RNA sequencing to identify differentially expressed genes (DEGs) between these two cell lines. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were used to understand the functional enrichment of these DEGs, focusing on metabolic pathways.

A key methodological innovation was the construction of a Metabolism Score. This score was derived from 14 metabolism-related genes (MRGs) identified through a multi-step process:

  1. Downloading a comprehensive list of MRGs from the Molecular Signatures Database.
  2. Identifying overlapping genes between the DEGs and MRGs.
  3. Using univariate Cox regression analysis on TCGA LUAD data to find survival-related MRGs.
  4. Employing LASSO regression to select the optimal set of 14 genes for the prognostic model.

This Metabolism Score was then used to stratify patients into high- and low-score groups. The study also utilized various bioinformatics tools and public databases for validation and further analysis, including:

  • Human Protein Atlas and TIMER2.0: To assess gene expression in normal and tumor tissues.
  • CIBERSORT and ssGSEA: To analyze immune cell infiltration in the tumor microenvironment.
  • ESTIMATE: To evaluate stromal and immune cell components.
  • TIDE and IMvigor210 cohort: To assess response to immunotherapy.
  • CellMiner: To explore the association between gene expression and drug sensitivity.
  • Western Blot and RT-qPCR: For experimental validation of gene expression.

Datasets

The study utilized several key datasets:

  • A549 and A549RR cell lines: For initial RNA sequencing and characterization of radiosensitive vs. radioresistant phenotypes.
  • The Cancer Genome Atlas (TCGA) lung adenocarcinoma dataset: (N=502) for identifying survival-related MRGs and constructing the prognostic model.
  • Three independent public datasets for validation:
    • GSE72094 (Lung Adenocarcinoma, N=398)
    • GSE3141 (Lung Cancer, N=110)
    • GSE8894 (Lung Cancer, N=138)
  • IMvigor210 immunotherapy cohort: For validating the association between Metabolism Score and response to immune checkpoint inhibitors (ICIs).
  • Human Protein Atlas and TIMER2.0: For gene expression analysis in normal and tumor tissues.
  • ImmPort database: For immune-related genes.
  • CellMiner: For drug sensitivity analysis.

No new benchmark datasets were introduced; the study relied on existing public repositories.

Key Insights and Ideas

  • Metabolic Reprogramming Drives Radioresistance: The study provides strong evidence that acquiring radiation resistance in LUAD is accompanied by significant metabolic reprogramming, affecting pathways like nucleotide/amino acid, lipid, and glucose metabolism.
  • A Unified "Metabolism Score" for Prognosis: The development of a single, quantifiable "Metabolism Score" based on 14 key genes offers a powerful tool to predict patient outcomes, moving beyond individual gene analysis.
  • Metabolism as a Bridge to Immunity and Drug Response: The most compelling insight is the demonstration that the Metabolism Score is not just a prognostic marker but also a predictor of immune cell infiltration, response to immunotherapy (ICIs), and drug vulnerability. This suggests that targeting metabolic pathways could simultaneously influence the tumor's immune microenvironment and its susceptibility to certain drugs.
  • Radiosensitivity is Linked to Immune Status: Differences in immune cell infiltration and immune factor expression were observed between high- and low-Metabolism Score groups, highlighting a crucial link between a tumor's metabolic state and its ability to evade or engage the immune system, particularly in the context of radiation resistance.

Key Results

  • Prognostic Model Performance: The developed Metabolism Score demonstrated good predictive accuracy, with an AUC of 0.72 for 1-3 year survival in the TCGA dataset.
  • Validation Success: The prognostic model was successfully validated across three independent LUAD datasets, consistently showing that patients with low Metabolism Scores had longer survival times.
  • Immune Checkpoint Inhibitor (ICI) Response: Patients with low Metabolism Scores exhibited significantly higher response rates to ICIs (p=0.0015), suggesting that metabolic status can predict immunotherapy efficacy.
  • Drug Vulnerability: The study identified specific drug vulnerabilities associated with high Metabolism Scores, indicating that these tumors might be more sensitive to platinum compounds, alkylating agents, and PARP inhibitors, while potentially resistant to topoisomerase inhibitors.
  • Gene Expression Differences: Out of the 14 hub genes, TRDMT1 and JMJD7.PLA2G4B were downregulated in LUAD compared to normal tissues, while the other 10 were upregulated.

Limitations and Future Work

  • Experimental Validation: While the study used Western Blot and RT-qPCR for some validation, further in-depth experimental validation of the identified MRGs and their specific roles in radiosensitivity, metabolism, and immune response is needed.
  • Mechanism Elucidation: The precise mechanisms by which many of the 14 identified genes influence radiosensitivity, tumorigenesis, and immune tolerance require further investigation.
  • Clinical Translation: The authors suggest that more basic experiments and the integration of multi-omics data (proteomics, single-cell sequencing) could help optimize this metabolic prognostic model for broader clinical application, especially for patients undergoing radiation therapy.
  • Target Identification: While the study identified potential drug targets, further research is needed to clarify the specific roles of genes like PPOX and DTYMK in radiosensitivity and immune systems.

Summary updated

Abstract

Metabolic reprogramming is a novel method for the treatment of malignant tumors. The exploration of metabolism procedures between radiosensitive and radioresistant tumors may provide novel perspectives for lung adenocarcinoma (LUAD) patients after radiation therapy. In our study, metabolic reprogramming and immune response changes were found between radioresistant cell line (A549RR) and its parent cells (A549) using gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Nucleotide/amino acid, lipid, and glucose metabolic process, including Alanine, aspartate and glutamate metabolism, Tryptophan/Tyrosine metabolism, Butanoate metabolism, Purine/Pyrimidine metabolism, were screened out. Then molecular signatures database and The Cancer Genome Atlas Program (TCGA) lung adenocarcinoma datasets were used to identify metabolism-related genes (MRGs) between radiosensitive and radioresistant lung adenocarcinoma (LUAD) cells. A metabolism-based prognostic model, receiver operating characteristic (ROC) curve and nomogram were constructed using Metabolism Score calculated by 14 metabolism-related genes (MRGs). Three independent public datasets, (GSE72094, GSE3141, GSE8894) and one immunotherapy cohort (IMvigor210) were used as external validation cohorts. Expression of 14 hub genes in cells, normal and LUAD specimens were explored by Human Protein Atlas, TIMER2.0 and RT-qPCR. Patients with low-Metabolism Scores were correlated with longer survival times, higher response rates to immune checkpoint inhibitors (ICIs), different immune cell infiltrations and drug vulnerability. Our study demonstrated a comprehensive landscape between radiosensitive and radioresistant LUAD, and provide novel targets for NSCLC, especially those patients received radiation therapy. Moreover, this metabolism-based prognostic model may help to investigate connections between radiosensitivity, immune response, metabolic reprogramming, and patients' prognosis.
BibTeX
@inproceedings{peng2022insight,
  author = {Shunli Peng and Rong Wang and Yuling Zhou and Wei Wei and Guihua Zhong and Xiaotao Huang and Shuai Yang and Qiaodan Liu and Zhigang Liu},
  title = {{Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.872910},
}
Figure